K562 (Chronic myeloid leukemia, Prof. Ufuk Gündüz Laboratory, Turkey) and CCRF-CEM (Acute lymphoid leukemia, DSMZ, Germany) cells were cultivated in 1X RPMI1640 medium (Medsantek/dist. Gibco, TR) enriched with 10% fetal bovine serum (Interlab/dist. BI, TR), 1% nonessential aminoacids (Interlab/dist. Sigma Aldrich, TR), and 1% penicillin/streptomycin (Interlab/dist. Sigma Aldrich, TR) in T25 cell culture flasks. Subculturing and drug resistance development procedures were presented in our previous work25. The same cells were used in this study after 4 passages. Based on IC50 analyses, K562 cells were classified as high-level laboratory drug resistant models with approximately 60-fold resistance to imatinib as compared to wild type K562 cells, while CCRF-CEM cells were categorized as a clinically relevant model with approximately fourfold resistance to doxorubicin as compared to their wild type progenies25,26.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.